ICMJE DISCLOSURE FORM

Date: 5/20/2026

Your Name: Janwillem WH Kocks

Manuscript Title: 10 vragen over Hoesten

Manuscript Number (if known): D9146

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	**Specifications/Comments (e.g., if payments were made to you or to your institution)**
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	AstraZeneca; Boehringer Ingelheim; Chiesi; Eli Lilly; GSK; Teva; ALK-Abello; Valneva	Specifications/Comments: Research grants or contracts; All fees go to GPRI.
3	Royalties or licenses	☒ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	AstraZeneca; Boehringer Ingelheim; Chiesi; Eli Lilly; GSK; MSD; Novo Nordisk; Sanofi; Teva; ALK-Abello Specifications/Comments: Consulting/advisory fees; All fees go to GPRI.	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	AstraZeneca; Boehringer Ingelheim; Chiesi; Eli Lilly; GSK; MSD; Novo Nordisk; Sanofi; Teva; ALK-Abello Specifications/Comments: Honoraria/lecture/presentation/educational event fees where applicable; All fees go to GPRI.	
6	Payment for expert testimony	☒ None	
7	Support for attending meetings and/or travel	AstraZeneca; Boehringer Ingelheim; GSK Specifications/Comments: Support for attending meetings and/or travel.	
8	Patents planned, issued or pending	☒ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	IPCRG board director; CAHAG science committee	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	Owner of General Practitioners Research Institute (GPRI); <5% shares of Lothar Medtec GmbH Specifications/Comments: Ownership/stock interests.	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None	
13	Other financial or non-financial interests		

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.